Wedbush Securities Inc. acquired a new position in Allena Pharmaceuticals Inc (NASDAQ:ALNA) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 15,400 shares of the company’s stock, valued at approximately $63,000.

Several other hedge funds have also recently made changes to their positions in ALNA. BlackRock Inc. lifted its holdings in shares of Allena Pharmaceuticals by 0.8% during the fourth quarter. BlackRock Inc. now owns 581,971 shares of the company’s stock valued at $3,172,000 after purchasing an additional 4,528 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Allena Pharmaceuticals by 8.1% during the fourth quarter. Geode Capital Management LLC now owns 72,314 shares of the company’s stock valued at $394,000 after purchasing an additional 5,444 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Allena Pharmaceuticals by 8.2% during the fourth quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock valued at $151,000 after purchasing an additional 2,118 shares during the last quarter. Finally, Sphera Funds Management LTD. lifted its holdings in shares of Allena Pharmaceuticals by 24.9% during the first quarter. Sphera Funds Management LTD. now owns 431,193 shares of the company’s stock valued at $3,027,000 after purchasing an additional 85,994 shares during the last quarter. Institutional investors own 67.89% of the company’s stock.

ALNA opened at $4.00 on Wednesday. Allena Pharmaceuticals Inc has a fifty-two week low of $3.62 and a fifty-two week high of $12.00. The business has a 50-day moving average of $4.38 and a 200-day moving average of $5.59. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.80 and a quick ratio of 6.80. The company has a market capitalization of $93.88 million, a PE ratio of -2.33 and a beta of 1.98.

Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.01). On average, equities research analysts expect that Allena Pharmaceuticals Inc will post -1.98 earnings per share for the current fiscal year.

ALNA has been the subject of several analyst reports. Cowen reaffirmed a “buy” rating on shares of Allena Pharmaceuticals in a report on Friday, August 9th. ValuEngine raised Allena Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Allena Pharmaceuticals in a report on Monday, August 12th. Zacks Investment Research downgraded Allena Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. Finally, Roth Capital reduced their price objective on Allena Pharmaceuticals from $61.00 to $31.00 in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.14.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Featured Article: What are the benefits of a portfolio tracker?

Want to see what other hedge funds are holding ALNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allena Pharmaceuticals Inc (NASDAQ:ALNA).

Institutional Ownership by Quarter for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.